# ScoreItem: Sódio

**ID:** `019bf31d-2ef0-7175-958b-2b260ae48a40`
**FullName:** Sódio (Exames - Laboratoriais)
**Unit:** mEq/L

**Preparation Metadata:**
- Quality Grade: **EXCELLENT**
- Total Chunks: 30 de 2 artigos
- Avg Similarity: 0.671

---

## Contexto

Você é um especialista em medicina funcional integrativa e está contribuindo com o **Escore Plenya** — um escore completo de análise de saúde que avalia todos os aspectos da saúde, performance e longevidade humana. Cada ScoreItem representa um parâmetro clínico, laboratorial, genético, comportamental ou histórico que compõe esse escore.

Seu papel é gerar conteúdo clínico de alta qualidade para enriquecer cada parâmetro do escore com relevância clínica, orientação ao paciente e conduta prática.

**Regras inegociáveis:**
- Use **apenas** o conhecimento médico real consolidado e os dados presentes nos chunks científicos abaixo
- **Não alucine, não invente** dados, estudos, estatísticas ou referências que não estejam nos chunks ou no seu conhecimento médico estabelecido
- Se um dado específico não constar nos chunks e não for do seu conhecimento consolidado, **não o inclua**
- Seja preciso: prefira omitir a inventar

## Instrução

Com base nos chunks científicos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7175-958b-2b260ae48a40`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7175-958b-2b260ae48a40",
  "clinical_relevance": "Texto técnico para médicos (1000-5000 chars): definição fisiológica precisa, valores de referência e interpretação, fisiopatologia resumida, dados epidemiológicos com números concretos, estratificação de risco baseada em evidências.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que é este parâmetro sem jargões, por que é importante para a saúde, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta clínica em Markdown (1000-5000 chars): investigação complementar necessária, critérios de encaminhamento a especialistas, intervenções baseadas em evidências. Use bullet points, seções e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto clínico: 1-9 pts
- Alto impacto clínico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Critérios: gravidade/mortalidade (40%), prevalência (30%), intervencionabilidade (30%)

---

### Contexto Científico

**ScoreItem:** Sódio (Exames - Laboratoriais)
**Unidade:** mEq/L

**30 chunks de 2 artigos (avg similarity: 0.671)**

### Chunk 1/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** results | **Similarity:** 0.739

ney Dis. 2013;62:13949. 
17. Garrahy A, Galloway I, Hannon AM, Dineen R, OKelly P, Tormey WP, OReilly MW, Williams DJ, Sherlock M, Thomp-son CJ. Fluid restriction therapy for chronic SIAD; Results of a prospective randomized controlled trial. J Clin Endocrinol Metab. 2020;105:dgaa619. 
18. Sterns RH. Adverse consequences of overly rapid correction of hyponatremia. Front Horm Res. 2019;52:13042. 
19. Garrahy A, Dineen R, Hannon AM, Cuesta M, Tormey W, Sher-lock M, Thompson CJ. Continuous versus bolus infusion of hypertonic saline in the treatment of symptomatic hyponatremia caused by SIAD. J Clin Endocrinol Metab. 2019;104:3595602. 
20. Baek SH, Jo YH, Ahn S, Medina-Liabres K, Oh YK, Lee JB, Kim S. Risk of overcorrection in rapid intermittent bolus vs slow continuous infusion therapies of hypertonic saline for patients with symptomatic hyponatremia: the SALSA rand-omized clinical trial. JAMA Intern Med. 2021;181:8192. 
21.

---

### Chunk 2/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.723

1])
Deﬁnition by biochemical test valueDeﬁnition by duration from onsetDeﬁnition by severity of neurological symptomsMild130  , < 135 (mmol/L)Acute < 48hNo or Minimal/MildAbsence or Presence of minimal/mild symptomsModerate125  , < 130 (mmol/L)Chronic  48h (or unknown)ModeratePresence of moderate symptomsSevere < 125 (mmol/L)SeverePresence of severe symptomsTable 2  Neurological symptoms of hyponatremia by severity (modiﬁed from a previous study [11])
SeverityNeurological symptomsNo or Minimal/MildDiﬃculty concentrating, irritability, altered mood, depression, unexplained headacheModerateAltered mental status, disorientation, confusion, unexplained nausea, gait instabilitySevereComa, obtundation, seizures, respiratory distress, vomiting

251Clinical and Experimental Nephrology (2025) 29:249–258 
Practice Guideline set an upper limit with serum  [Na+] < + 10mmol/L/d.

---

### Chunk 3/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.718

AR, Chonchol M. Serum sodium and cognition in older community-dwelling men. Clin J Am Soc Nephrol. 2018;13:36674. 9. Warren AM, Grossmann M, Christ-Crain M, Russell N. Syn-drome of inappropriate antidiuresis: from pathophysiology to management. Endocr Rev. 2023;44:81961. 
10. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E, Hyponatraemia Guideline Development Group. Clini-cal practice guideline on diagnosis and treatment of hyponatrae-mia. Eur J Endocrinol. 2014;170:147. 
11. Verbalis JG. Emergency management of acute and chronic hyponatremia. In: Matﬁn G, editor. Endocrine and metabolic emergencies. Washington: Endocrine Communications Press; 2014. p. 359. 
12. Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ. Diagnosis, evaluation, and treat-ment of hyponatremia: expert panel recommendations.

---

### Chunk 4/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** discussion | **Similarity:** 0.704

Clinical and Experimental Nephrology (2025) 29:249–258 https://doi.org/10.1007/s10157-024-02606-3
INVITED REVIEW ARTICLE
Treatment ofhyponatremia: comprehension andbest clinical practiceHirofumiSumi1,2· NaotoTominaga1,2 
· YoshiroFujita3· JosephG.Verbalis4· the Electrolyte Winter Seminar Collaborative GroupReceived: 8 July 2024 / Accepted: 29 November 2024 / Published online: 23 January 2025 © The Author(s) 2025AbstractThis review article series on water and electrolyte disorders is based on the Electrolyte Winter Seminar held annually for young nephrologists in Japan. The seminar features dynamic case-based discussions, some of which are included as self-assessment questions in this series. The second article in this series focuses on treatment of hyponatremia, a common water and electrolyte disorder frequently encountered in clinical practice.

---

### Chunk 5/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** introduction | **Similarity:** 0.701

mon water and electrolyte disorder frequently encountered in clinical practice. Hyponatremia presents diagnostic challenges due to its various etiologies and the presence of co-morbidities that aﬀect water and electrolyte homeostasis. Furthermore, limited evidence, including a lack of robust randomized controlled trials, complicates treatment decisions and increases the risk of poor outcomes from inappropriate management of both acute and chronic hyponatremia. This review provides a comprehensive overview of treatment of hyponatremia for better comprehension and improved clinical practice.Keywords Hyponatremia· Treatment· Overly rapid correction· Osmotic demyelination syndromeIntroductionHyponatremia is the most frequently encountered electrolyte disorder in daily clinical practice [1, 2]. The pathophysiol-ogy of hyponatremia is often diﬃcult to interpret and evalu-ate due to multiple additional factors involved, which makes the choice of appropriate treatment challenging.

---

### Chunk 6/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.699

on. Clin Exp Nephrol. 2004;8:98102. 
41. Ormonde C, Cabral R, Serpa S. Osmotic demyelination syndrome in a patient with hypokalemia but no hyponatremia. Case Rep Nephrol. 2020;2020:3618763. 
42. Nagase K, Watanabe T, Nomura A, Nagase FN, Iwasaki K, Naka-mura Y, Ikai H, Yamamoto M, Murai Y, Yokoyama-Kokuryo W, Takizawa N, Shimizu H, Fujita Y. Predictive correction of serum sodium concentration with formulas derived from the Edelman equation in patients with severe hyponatremia. Sci Rep. 2023;13:1783. 
43. George JC, Zafar W, Bucaloiu ID, Chang AR. Risk factors and outcomes of rapid correction of severe hyponatremia. Clin J Am Soc Nephrol. 2018;13:98492. 
44. MacMillan TE, Shin S, Topf J, Kwan JL, Weinerman A, Tang T, Raissi A, Koppula R, Razak F, Verma AA, Fralick M. Osmotic demyelination syndrome in patients hospitalized with hypona-tremia. NEJM Evid. 2023; 2:EVIDoa2200215. 
45.

---

### Chunk 7/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.697

on syndrome in patients hospitalized with hypona-tremia. NEJM Evid. 2023; 2:EVIDoa2200215. 
45. Sterns RH, Rondon-Berrios H, Adrogué HJ, Berl T, Burst V, Cohen DM, Christ-Crain M, Cuesta M, Decaux G, Emmett M, Garrahy A, Gankam-Kengne F, Hix JK, Hoorn EJ, Kamel KS, Madias NE, Peri A, Refardt J, Rosner MH, Sherlock M, Silver SM, Soupart A, Thompson CJ, Verbalis JG, PRONATREOUS Investigators. Treatment guidelines for hyponatremia: stay the course. Clin J Am Soc Nephrol. 2024;19:12935. 
46. MacMillan TE, Tang T, Cavalcanti RB. Desmopressin to prevent rapid sodium correction in severe hyponatremia: a systematic review. Am J Med. 2015;128(1362):e15-24. 
47. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:15819. 
48. Sood L, Sterns RH, Hix JK, Silver SM, Chen L. Hypertonic saline and desmopressin: a simple strategy for safe correction of severe hyponatremia. Am J Kidney Dis. 2013;61:5718. 
49. Wang C, Lebedeva V, Yang J, Anih J, Park LJ, Paczkowski F, Roshanov PS.

---

### Chunk 8/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** methods | **Similarity:** 0.694

rying treatment goals and methods recommended by diﬀerent guidelines [10, 12]. However, understanding the principles of treatment is crucial because of many commonalities across diﬀerent guidelines and recommen-dations. The six principles of treatment are as follows:1. Correct promptly with hypertonic saline (usually 3% saline) if acute and symptomatic (moderate-to-severe).2. If chronic/asymptomatic or minimally/mildly symptomatic, correct at a moderate rate, regardless of the correction method.3. Discontinue medications associated with impaired renal free water excretion or natriuresis.4. Adhere to upper correction limit if in patients at high risk for developing osmotic demyelination syndrome (ODS), except in acute/symptomatic (moderate-to-severe) cases.5. If overly rapidly corrected, re-lower to low serum  [Na+] with 5% dextrose (D5W) and/or desmopressin in carefully selected patients.6.

---

### Chunk 9/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** methods | **Similarity:** 0.692

vision ofNephrology andHypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Shukugawara, Tama-Ku, Kawasaki, Kanagawa214-8525, Japan2 Division ofNephrology andHypertension, Department ofInternal Medicine, St. Marianna University School ofMedicine, 2-16-1, Sugao, Miyamae-Ku, Kawasaki, Kanagawa216-8511, Japan3 Department ofNephrology, Chubu Rosai Hospital, 1-10-6, Komei-Cho, Minato-Ku, Nagoya, Aichi455-8530, Japan4 Division ofEndocrinology andMetabolism, Department ofMedicine, Georgetown University, 4000 Reservoir Rd NW, Washington, DC20007, USA

250
 Clinical and Experimental Nephrology (2025) 29:249–258
Common principles oftreatment ofhyponatremiaTreatment of hyponatremia is usually more challenging than that of other electrolyte disorders due to its complex-ity and varying treatment goals and methods recommended by diﬀerent guidelines [10, 12].

---

### Chunk 10/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.691

apies of hypertonic saline for patients with symptomatic hyponatremia: the SALSA rand-omized clinical trial. JAMA Intern Med. 2021;181:8192. 
21. Pelouto A, Refardt JC, Christ-Crain M, Zandbergen AAM, Hoorn EJ. Overcorrection and undercorrection with ﬁxed dos-ing of bolus hypertonic saline for symptomatic hyponatremia. Eur J Endocrinol. 2023;188:32230.

258
 Clinical and Experimental Nephrology (2025) 29:249–258
 
22. Chen S, Shey J, Chiaramonte R. Ratio proﬁle: physiologic approach to estimating appropriate intravenous ﬂuid rate to manage hyponatremia in the syndrome of inappropriate anti-diuresis. Kidney360. 2022;3:21839. 
23. Edelman IS, Leibman J, OMeara MP, Birkenfeld LW. Interrela-tions between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water. J Clin Invest. 1958;37:123656. 
24. Rose BD. New approach to disturbances in the plasma sodium concentration. Am J Med. 1986;81:103340. 
25.

---

### Chunk 11/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.685

gy (2025) 29:249–258 
Practice Guideline set an upper limit with serum  [Na+] < + 10mmol/L/d. Therefore, since treatment aims to improve cerebral edema and resolve symptoms, increasing serum  [Na+] more than needed is unnecessary once symptoms are resolved.However, if no non-osmotic arginine vasopressin (AVP) secretion occurs (i.e., appropriate osmotic suppression), as observed in acute water intoxication, serum  
[Na+] may rap-idly improve to normal concentrations with a large amount of diluted urine excretion after the treatment initiation. 
Fig. 1  Hyponatremia treatment algorithm based on neurologi-cal symptoms (modiﬁed from a previous study[11]). The arrows between the symptom boxes indicate movement of patients between diﬀerent symptom levels. 1Some authors recommend simultaneous treatment with desmopressin to limit speed of serum  [Na+] correc-tion.

---

### Chunk 12/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** discussion | **Similarity:** 0.667

erum  
[Na+] and urine output should be measured every 2h until the condition stabilizes [10]. A more recent retro-spective analysis of 22,858 hospitalizations over 10years with  [Na+] < 130mmol/L similarly showed a high rate of correction > 8mmol/L (17.7%) but a low rate of ODS (0.05%) [44]. This has led to a reconsideration of the rec-ommended rates of hyponatremia correction, but until more deﬁnitive studies are conducted, current expert opinion still recommends correcting cautiously in patients with a serum  [Na+] < 120mmol/L: correction of serum  [Na+] by  10mmol/L within 24h or by  18mmol/L within 48h in most patients, but correction by  8mmol/L within 24h in patients with additional risk factors for ODS [45].The three treatment strategies for overly rapid correction of hyponatremia are proactive, reactive, and rescue [46].

---

### Chunk 13/30
**Article:** Serum sodium within the normal range and its U-shaped relationship with biological aging in U.S. adults (2026)
**Journal:** Revista não identificada
**Section:** discussion | **Similarity:** 0.666

tus (
15
). However, due to its limited routine clinical 
application, indirect measures such as serum sodium, urine specic 
gravity, or urine color are commonly used to reect hydration status. 
When hyperglycemia and renal failure are absent, serum sodium 
levels predominantly inuence plasma osmolality (
16
, 
17
), establishing 
it as a key indicator of hydration status (
18
).
Evidence from previous cohort analyses suggests that serum 
sodium concentrations may serve as a predictive biomarker for 
morbidity and mortality. A cross-sectional analysis of adults aged 
5170 with serum sodium concentrations below 135 mmol/L or above 
145 mmol/L demonstrated that inadequate hydration was linked to a 
higher likelihood of adverse health outcomes and mortality (
19
).

---

### Chunk 14/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.665

, total exchangeable potassium and total body water. J Clin Invest. 1958;37:123656. 
24. Rose BD. New approach to disturbances in the plasma sodium concentration. Am J Med. 1986;81:103340. 
25. Berl T. Impact of solute intake on urine ﬂow and water excre-tion. J Am Soc Nephrol. 2008;19:10768. 
26. Monnerat S, Atila C, Baur F, Santos de Jesus J, Refardt J, Dick-enmann M, Christ-Crain M. Eﬀect of protein supplementation on plasma sodium levels in the syndrome of inappropriate anti-diuresis: a monocentric, open-label, proof-of-concept study-the TREASURE study. Eur J Endocrinol. 2023; 189:25261. 
27. Lockett J, Berkman KE, Dimeski G, Russell AW, Inder WJ. Urea treatment in ﬂuid restriction-refractory hyponatraemia. Clin Endo-crinol (Oxf). 2019;90:6306. 
28. Pelouto A, Monnerat S, Refardt J, Zandbergen AAM, Christ-Crain MC, Hoorn EJ. Clinical factors associated with hyponatremia cor-rection during treatment with oral urea. Nephrol Dial Transplant. 2024;16:gfae164. 
29.

---

### Chunk 15/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.663

2014. p. 359. 
12. Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ. Diagnosis, evaluation, and treat-ment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(Supplement 1):S1-42. 
13. Perianayagam A, Sterns RH, Silver SM, Grieﬀ M, Mayo R, Hix J, Kouides R. DDAVP is eﬀective in preventing and revers-ing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol. 2008;3:3316. 
14. Sterns RH, Nigwekar SU, Hix JK. The treatment of hypona-tremia. Semin Nephrol. 2009;29:28299. 
15. Koenig MA, Bryan M, Lewin JL 3rd, Mirski MA, Geocadin RG, Stevens RD. Reversal of transtentorial herniation with hyper-tonic saline. Neurology. 2008;70:10239. 
16. Hoorn EJ, Zietse R. Hyponatremia and mortality: moving beyond associations. Am J Kidney Dis. 2013;62:13949. 
17. Garrahy A, Galloway I, Hannon AM, Dineen R, OKelly P, Tormey WP, OReilly MW, Williams DJ, Sherlock M, Thomp-son CJ.

---

### Chunk 16/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.659

14;120:74451. 
37. Arima H, Goto K, Motozawa T, Mouri M, Watanabe R, Hirano T, Ishikawa SE. Open-label, multicenter, dose-titration study to determine the eﬃcacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secre-tion of antidiuretic hormone. Endocr J. 2021;68:1729. 
38. Kleindienst A, Georgiev S, Schlaﬀer SM, Buchfelder M. Tolvap-tan versus fluid restriction in the treatment of hyponatremia resulting from SIADH following pituitary surgery. J Endocr Soc. 2020;4:bvaa068. 
39. Singh TD, Fugate JE, Rabinstein AA. Central pontine and extrapontine myelinolysis: a systematic review. Eur J Neurol. 2014;21:144350. 
40. Nguyen MK, Kurtz I. Role of potassium in hypokalemia-induced hyponatremia: lessons learned from the Edelman equation. Clin Exp Nephrol. 2004;8:98102. 
41. Ormonde C, Cabral R, Serpa S. Osmotic demyelination syndrome in a patient with hypokalemia but no hyponatremia. Case Rep Nephrol. 2020;2020:3618763. 
42.

---

### Chunk 17/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.658

cor-rection (serum  [Na+] > + 8mmol/L in 24h) occurred in as many as 41% of the patients, but ODS occurred in only 0.5% of the hyponatremic patients [43]. The study also showed the following risk factors for overly rapid correc-tion of hyponatremia: young age (63 vs. 68years), female sex, schizophrenia, low Charlson Comorbidity Index, low serum  [Na+] at the initial visit, and urine  
[Na+] < 30mmol/L [43]. Among these risk factors, which are often experienced in clinical practice, low urine  [Na+] is compellingly asso-ciated with overly rapid correction of hyponatremia.

---

### Chunk 18/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** methods | **Similarity:** 0.657

[1, 2]. The pathophysiol-ogy of hyponatremia is often diﬃcult to interpret and evalu-ate due to multiple additional factors involved, which makes the choice of appropriate treatment challenging. Further-more, there is an insuﬃciency of evidence-based treatment options for hyponatremia, which often necessitates a trial-and-error approach to treatment and may result in unfa-vorable outcomes in hyponatremic patients. With this back-ground, new ﬁndings on treatment methods for the syndrome of inappropriate antidiuresis (SIAD), including vasopressin receptor antagonists (vaptans), hypertonic saline, and urea have recently been reported.Clinicians should appropriately treat hyponatremia through appropriate evaluation based on pathophysiol-ogy, since not only acute moderate-to-severe symptomatic hyponatremia but also chronic minimal/mild symptomatic hyponatremia are associated with unfavorable outcomes [39].

---

### Chunk 19/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.656

, re-lower to low serum  [Na+] with 5% dextrose (D5W) and/or desmopressin in carefully selected patients.6. Perform frequent blood tests and monitor urine output after treatment initiation.If acute/symptomatic (moderate-to-severe) symptoms are suspected, treatment should be initiated with 3% saline (Fig.1) [11]. Overly rapid correction can be prevented by closely monitoring the serum  [Na+] and the urine out-put after treatment initiation, even if hyponatremia is not acute/symptomatic (moderate-to-severe). Additionally, even if an overly rapid correction occurs, there should be no concern regarding treating hyponatremia excessively, since re-lowering to low serum  [Na+] can reduce the risk of developing ODS [13].When treating patients with hyponatremia, it is practical to assess extracellular ﬂuid volume and urine osmolality  (UOsm) simultaneously, with understanding the mechanisms of urinary dilution and concentration in the context of treatment.

---

### Chunk 20/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.654

, starting at 30g/d is common. In a recent observational study involving inpatients with hyponatremia (plasma  [Na+] < 135mmol/L), 161 treatment episodes of urea were administered to 140 patients, with 93% diagnosed with SIAD. Patients received a median dose of 30g/d of urea for 4days, either in combination with ﬂuid restriction or alone. The resulting serum  [Na+] increased by 7mmol/L over the 4-day period, with normalization of serum  [Na+] occurring in 47% of treatment episodes, while overly rapid correction was noted in only 3% (5 cases). In the ﬁve cases of overly rapid correction, oral urea and ﬂuid restriction were discontinued in four and three patients, respectively. Additionally, three of these ﬁve patients received plasma  [Na+] re-lowering therapy (two with hypotonic ﬂuids only and one with hypotonic ﬂuids plus desmopressin) [28]. The increase in urine volume due to oral urea is determined by dividing the increase in urea excretion by urine osmolality.

---

### Chunk 21/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.651

ry concentrating ability when treating hyponatremia(1) Administer urea and/or NaCl(2) Use V2 receptor antagonists

252
 Clinical and Experimental Nephrology (2025) 29:249–258
Contextually, the U.S. Expert Panel Recommendations state that true acute hyponatremia does not require an upper limit of serum  [Na+] [12], although determining true symptomatic hyponatremia is sometimes diﬃcult. Therefore, treating symptomatic hyponatremia is reasonable with 3% saline and an upper limit of serum  [Na+]. Conversely, the European Clinical Practice Guideline set the above-men-tioned upper correction limits [10].

---

### Chunk 22/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.650

ular ﬂuid volume and urine osmolality  (UOsm) simultaneously, with understanding the mechanisms of urinary dilution and concentration in the context of treatment. Renal electrolyte-free water excretion is necessary to increase the serum  [Na+]. Therefore, treatment should be directed toward eliminating any factors that contribute to impaired urinary dilution, and intentionally impairing the urinary concentrating mechanism is warranted (Table3).Treatment goals andupper correction limits ofhyponatremia: notidentical betweentheU.S. Expert Panel Recommendations andtheEuropean Clinical Practice GuidelineAcute/symptomatic (moderate-to-severe) hyponatremiaThe treatment principle of acute/symptomatic hypona-tremia is to promptly elevate serum  [Na+] to decrease cer-ebral edema and improve neurological symptoms. Here, we compare the U.S. Expert Panel Recommendations and the European Clinical Practice Guideline for treatment goals (Table4) [10, 12].

---

### Chunk 23/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.650

atic (moderate-to-severe)Goal: + 4 to 6mmol/L/dUpper correction limit: noneGoal: + 5mmol/L/dUpper correction limit: + 10mmol/L/dChronic/asymptomatic or symptomatic (minimal/mild)Goals: + 4 to 8mmol/L/d, + 4 to 6mmol/L/d (ODS high risk)Upper correction limits: + 10 to 12mmol/L/d, + 8mmol/L/d (ODS high risk)Goal: noneUpper correction limit: + 10mmol/L/d

253Clinical and Experimental Nephrology (2025) 29:249–258 
Europeans and North Americans. Regardless of the method selected, monitoring serum  [Na+], urine output, and  UOsm or urine speciﬁc gravity frequently (every 24h) is more crucial. A recent report showed that the Edelman equation is useful for predicting the increase in serum  [Na+] (Fig.2) [22].Fluid restriction andsolute loadingAs evident from the Edelman equation [23, 24], the serum  [Na+] can be increased by decreasing the denominator, total body water, and increasing the numerators,  Na+ and potassium  (K+).

---

### Chunk 24/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.648

other treatments [17]. In an RCT comparing ﬂuid restriction ( 1 L/d) without speciﬁc treatment for SIAD due to chronic moderate hyponatremia, median plasma  [Na+] increased from baseline by 4mmol/L [interquartile range (IQR) 26] with ﬂuid restriction, com-pared with 1mmol/L (IQR 01) with no speciﬁc treatment (P = 0.04). However, there was not a great diﬀerence with 
serum [Na+]t=
serum[Na+]0 x TBWTBW
-Urine ([Na+] + [K+])x (Rateux t)
+ Infusion ([Na+] + [K+])x (Rateivfx t)
+ (Rateivfx t)
-(Rateux t)serum [Na+]0=
total (Na++ K+)TBW
total (Na++ K+)=serum [Na+]0 x TBWEquation
1Equation
2(Na++ K+) added by infusion(Na++ K+) lost from urine
Volume added by infusionVolume lost from urine
Fig. 2  Prediction equation for correction of hyponatremia using the Edelman equation (modiﬁed from a previous study[22]). In Eq.1, the total  (Na+ +  K+) in the body before treatment is calculated using the Edelman equation.

---

### Chunk 25/30
**Article:** Serum sodium within the normal range and its U-shaped relationship with biological aging in U.S. adults (2026)
**Journal:** Revista não identificada
**Section:** other | **Similarity:** 0.647

. (2020) 225:11723. doi: 
10.1016/j.jpeds.2020.04.048
 23. Ostrominski JW, Mha SVA, Javedbutler M, Fonarow GC, Hirsch JS, Ms SRP, et al. 
Prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, 
1999-2020. 
JAMA Cardiology
. (2023) 8:1050. doi: 
10.1001/jamacardio.2023.3241
 24. Katz M. Hyperglycemia-induced hyponatremia  calculation of expected serum 
sodium depression. 
N Engl J Med
. (1973) 289:8434. doi: 
10.1056/NEJM197310182891607
 25. Stookey JD, Barclay D, Arie A, Popkin BM. e altered uid distribution in obesity 
may reect plasma hypertonicity. 
Eur J Clin Nutr
. (2007) 61:1909. doi: 
10.1038/sj.ejcn.1602521
 26. Klemera P, Doubal S. A new approach to the concept and computation of 
biological age. 
Mech Ageing Dev
. (2006) 127:2408. doi: 
10.1016/j.mad.2005.10.004
 27. Oh SW, Baek SH, An JN, Goo HS, Kim S, Na KY, et al. Small increases in plasma 
sodium are associated with higher risk of mortality in a healthy population.

---

### Chunk 26/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** results | **Similarity:** 0.643

e plasma sodium levels in patients with the syndrome of inappropriate anti-diuresis. J Am Soc Nephrol. 2020;31:61524. 
32. Refardt J, Imber C, Nobbenhuis R, Sailer CO, Haslbauer A, Mon-nerat S, Bathelt C, Vogt DR, Berres M, Winzeler B, Bridenbaugh SA, Christ-Crain M. Treatment eﬀect of the SGLT2 inhibitor empagliﬂozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crosso-ver trial. J Am Soc Nephrol. 2023;34:32232. 
33. Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, Hare MJL, Calder GL, Epa DS, George EM, Giri R, Kotowicz MA, Kyi M, Lafontaine N, MacIsaac RJ, Nolan BJ, ONeal DN, Renouf D, Varadarajan S, Wong J, Xu S, Bach LA. SGLT2 inhibi-tors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019;104:307787. 
34. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czer-wiec FS, Orlandi C, SALT Investigators.

---

### Chunk 27/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.641

ymptomatic hyponatremia but also chronic minimal/mild symptomatic hyponatremia are associated with unfavorable outcomes [39]. Therefore, this review aimed to provide a detailed overview of hyponatremia management to support clinicians in optimizing treatment strategies in clinical practice.Treatment ofhyponatremiaDeﬁnition ofhyponatremiaHyponatremia is classiﬁed into diﬀerent categories accord-ing to the duration after disease onset (acute or chronic), serum sodium concentration  ([Na+]) (mild, moderate, or severe), and the severity of neurological symptoms (no or minimal/mild, moderate, or severe). Clinicians must under-stand these three classiﬁcations not only for diagnosis but also for treatment (Tables1 and 2) [10, 11].

---

### Chunk 28/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.638

S, Refardt J, Zandbergen AAM, Christ-Crain MC, Hoorn EJ. Clinical factors associated with hyponatremia cor-rection during treatment with oral urea. Nephrol Dial Transplant. 2024;16:gfae164. 
29. Sterns RH, Rondon-Berrios HB. Urea for hyponatremia: a role for desmopressin? Nephrol Dial Transplant. 2024;22:gfae69. 
30. Krisanapan P, Vongsanim S, Pin-On P, Ruengorn C, Noppakun K. Eﬃcacy of furosemide, oral sodium chloride, and ﬂuid restriction for treatment of syndrome of inappropriate antidiuresis (SIAD): an open-label randomized controlled study (The EFFUSE-FLUID Trial). Am J Kidney Dis. 2020;76:20312. 
31. Refardt J, Imber C, Sailer CO, Jeanloz N, Potasso L, Kutz A, Wid-mer A, Urwyler SA, Ebrahimi F, Vogt DR, Winzeler B, Christ-Crain M. A randomized trial of empagliﬂozin to increase plasma sodium levels in patients with the syndrome of inappropriate anti-diuresis. J Am Soc Nephrol. 2020;31:61524. 
32.

---

### Chunk 29/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.637

 cits. Am J Med. 2006;119(71):e1-8. 5. Verbalis JG, Barsony J, Sugimura Y, Tian Y, Adams DJ, Carter EA, Resnick HE. Hyponatremia-induced osteoporosis. J Bone Miner Res. 2010;25:55463. 6. Usala RL, Fernandez SJ, Mete M, Cowen L, Shara NM, Bar-sony J, Verbalis JG. Hyponatremia is associated with increased osteoporosis and bone fractures in a Large US health system population. J Clin Endocrinol Metab. 2015;100:302131. 7. Fujisawa H, Sugimura Y, Takagi H, Mizoguchi H, Takeuchi H, Izumida H, Nakashima K, Ochiai H, Takeuchi S, Kiyota A, Fukumoto K, Iwama S, Takagishi Y, Hayashi Y, Arima H, Komatsu Y, Murata Y, Oiso Y. Chronic hyponatremia causes neurologic and psychologic impairments. J Am Soc Nephrol. 2016;27:76680. 8. Nowak KL, Yaﬀe K, Orwoll ES, Ix JH, You Z, Barrett-Connor E, Hoffman AR, Chonchol M. Serum sodium and cognition in older community-dwelling men. Clin J Am Soc Nephrol. 2018;13:36674. 9. Warren AM, Grossmann M, Christ-Crain M, Russell N.

---

### Chunk 30/30
**Article:** Treatment of hyponatremia: comprehension and best clinical practice (2025)
**Journal:** Clinical and Experimental Nephrology
**Section:** other | **Similarity:** 0.631

ut hyponatremia but with multiple ODS risk factors, who developed ODS during treatment to correct serum  [K+] [41]. Although this is a rare case, overly rapid correction is common in patients with hyponatremia and concomitant hypokalemia, particularly due to thiazide use. Using the Edelman equation to treat hyponatremia can reduce the fre-quency of overly rapid corrections and ensure an appropri-ate correction rate [42]. Therefore, the Edelman equation should be used to predict response to therapy, particularly in patients with concomitant hypokalemia, but with the limita-tion that all equations fail to include the eﬀect of a secondary aquaresis to rapidly increase the serum  
[Na+].An observational study of 1490 patients with admission serum  [Na+] < 120mmol/L showed that overly rapid cor-rection (serum  [Na+] > + 8mmol/L in 24h) occurred in as many as 41% of the patients, but ODS occurred in only 0.5% of the hyponatremic patients [43].

---

